Document:

Exhibit 10.1

 

Fourth Addendum to Asset Purchase
Agreement

 

This Fourth Addendum
to Asset Purchase Agreement (“Fourth Addendum”) is effective as on the date the parties have fully signed the
Fourth Addendum (“Effective Date of the Fourth Addendum”) and memorializes an agreement reached between PharmaCyte
Biotech, Inc., formerly Nuvilex, Inc. (“Licensee”), and SG Austria Pte. Ltd. (“Licensor”)
on 30 August 2017, as amended, relating to the Asset Purchase Agreement between the Parties dated as of the 26th day
of May 2011 (“Asset Purchase Agreement”), as amended by the Asset Purchase Agreement Addendum dated as of June
11, 2011, the Asset Purchase Agreement Addendum Number 2 dated as of June 14, 2012, the December 3, 2012 extension letter from
SG Austria, the Third Addendum to Asset Purchase Agreement dated as of June 25, 2013 (“Third Addendum”) and
the Clarification Agreement to Third Addendum to Asset Purchase Agreement dated as of June 25, 2013 (“Clarification Agreement”).
Licensee and Licensor are referred to in this Fourth Addendum individually as a “Party” and collectively as
the “Parties.” Defined terms in the Asset Purchase Agreement, Third Addendum and Clarification Agreement (collectively,
“Agreements”) have the same meaning in this Fourth Addendum as they do in the Agreements.

 

Recitals

 

		A.	The Parties entered into the Licensing Agreement to, among other things, provide Licensee with an exclusive worldwide license
to use the Cell-in-a-Box® Trademark and its Associated Technology with genetically modified HEK293 cells overexpressing
the cytochrome P450 2B1 gene specifically designed for the treatment of cancer to conduct research, to use in preclinical studies
and clinical trials, to obtain marketing approval and to market and sell products and treatments utilizing the Cell-in-a-Box®
Trademark and its Associated Technology world-wide;

 

		B.	Section 6.a. of the Third Addendum provides that Licensee shall pay to Licensor royalties equal
to two percent (2%) of Gross Sales received by Licensee or its Affiliates. The Parties desire to change the amount of royalties
Licensee shall pay to Licensor in accordance with the amended Section 6.a. below;

 

		C.	Section 6.b. of the Third Addendum provides that Licensee shall pay to Licensor royalties equal
to ten percent (10%) of the amount received by Licensee from Sub-Licensees on Sub-Licensees’ Gross Revenue. The Parties desire
to change the amount of royalties Licensee shall pay to Licensor in accordance with the amended Section 6.b. below;

 

		D.	Section 6.c. and 6.d. of the Third Addendum provides Licensee shall pay Licensor certain milestone
payments upon the occurrence of certain events (“Milestone Payments”). The Parties desire to delete Sections 6.c. and
6.d.;

 

		E.	The Parties desire to add a new Section 6.c. to the Third Addendum in accordance with the new Section
6.c. below;

 

		F.	The Parties desire to add a new Section 6.d. to the Third Addendum in accordance with the new Section
6.d. below;

 

		G.	The Parties desire to add a new Section 7.e. to the Third Addendum in accordance with the new Section
7.e. below;

 

		H.	The Parties desire to add a new Section 7.f. to the Third Addendum in accordance with the new Section
7.f below; and

 

		I.	The Parties desire to update the name of Licensee and each Party’s address of its registered
office and principal place of business.

 

 

 

    	 	1	 

     

    

 

Agreement

 

For good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, the Third Addendum is
hereby amended as follows:

 

		1.	In the preamble to the Third Addendum, the address of the registered office and principal place
of business of Licensee shall be amended to read: “SG Austria Pte. Ltd., a Singapore corporation having its registered office
and principal place of business at 3 Biopolis Drive, #05-19 Synapse, Singapore 138623 and its Affiliates (“Licensor”),
and”

 

		2.	In the preamble to the Third Addendum, the name of Licensee shall be amended to its new name and
address to read: “PharmaCyte Biotech, Inc., a Nevada corporation having its principal place of business at 23046 Avenida
de la Carlota, Suite 600, Laguna Hills, California 92653 USA and its Affiliates (“Licensee”).”

 

		3.	Section 6 of the Third Addendum shall be deleted and the following inserted in its place: “Royalties
and Other Consideration. After the transfer of the Purchased Assets, Licensee will make royalty and other payments to Licensor
as follows:”

 

		4.	Section 6.a. of the Third Addendum shall be deleted and the following inserted in its place: “Four
percent (4%) on all Gross Sales received by Licensee or its Affiliates;”

 

		5.	Section 6.b. of the Third Addendum shall be deleted and the following inserted in its place: “Twenty
percent (20%) of the amount received by Licensee from Sub-Licensees on Sub-Licensees Gross Revenues; provided, however,
that in the event the sublicensing royalty rate received by Licensee is four percent (4%) or less, Licensor shall receive fifty
percent (50%) of the amount of money received by Licensee from Sub-Licensees. For any amount received by Licensee over the sublicensing
royalty rate of four percent (4%), Licensor shall receive twenty percent (20%) of that amount.” For the avoidance of doubt
the following two examples are given. Example 1: Sub-Licensee has a Gross Sales Value of One Thousand Dollars US (US$1000.00).
Licensee receives a four percent (4%) royalty rate from Sub-Licensee equal to Forty Dollars US (US$40.00). In this example, Licensee
pays Licensor 50% of this royalty in the amount of Twenty Dollars US (US$20.00). Example 2: Sub-Licensee has a Gross Sales Value
of One Thousand Dollars US (US$1000.00). Licensee receives a six percent (6%) royalty rate from Sub-Licensee in the amount of Sixty
Dollars US (US$60.00) USD). In this example, Licensee pays Licensor 50% of the amount corresponding to a four percent royalty in
the amount of Twenty Dollars US (US$20.00) and twenty percent (20%) of the amount over four percent (4%) (20% of US$20.00 is equal
to US$4.00) to give a total royalty to Licensor of Twenty-Four Dollars US (US$24.00).

 

		6.	Sections 6.c. and 6.d. of the Third Addendum shall be deleted so that no Milestone Payments are
due pursuant to the Third Addendum and the following Section 6.c inserted in their place: “Except as otherwise provided in
Section 6.b., Licensor shall receive fifty percent (50%) of any other financial and non-financial consideration Licensee receives
from a Sub-Licensee.”

 

		7.	A new Section 6.d. shall be added to the Third Addendum to read as follows: “All payments due pursuant to Section 6.a
shall be paid within thirty (30) days of the end of the relevant calendar quarter. All payments due pursuant to Sections 6.b. and
6.d. shall be paid within forty-five (45) days after the calendar quarter in which the payment is received by Licensee from a Sub-Licensee.”

 

		8.	A new Section 6.e. shall be added to the Third Addendum to read as follows: Licensee shall pay an aggregate total amount of
Nine Hundred Thousand Dollars US (US$900,000.00) to Austrianova ratably over a nine (9) month period in the amount of two (2) Fifty
Thousand Dollars US (US$50,000.00) payments each month during the nine (9) month period on the days of the month to be agreed upon
between the parties, with a cure period of twenty (20) calendar days after receipt by Licensee of written notice from Licensor
that Licensee has failed to pay timely a monthly payment of One Hundred Thousand Dollars US (US$100,000) required by this Section
6.e.”

 

 

 

 

    	 	2	 

     

    

 

		9.	A new Section 7.f. shall be added to the Third Addendum to read as follows: “Licensee shall have an irrevocable right
of first refusal (“ROFR”) to purchase the Cell-in-a-Box® Trademark and its Associated Technology
(as defined in the Clarification Agreement) and all associated intellectual property, technology and/or trade secrets, including,
but not limited to, a non-exclusive license of the cellulose sulfate Licensor or Austrianova utilizes with the Cell-in-a-Box®
encapsulation technology and any manufacturing facility utilizing the Technologies.” The ROFR shall have a term of five (5)
years from August 30, 2017. Licensor shall notify Licensee in of its intention to pursue a transaction to sell, transfer or assign
the Technologies, in whole or in part (“Proposed Transaction”), including the material terms thereof, by providing
Licensee written notice thereof by an international courier service addressed to Licensee. If Licensee fails to exercise its ROFR
with respect to any Proposed Transaction within sixty (60) business days after its receipt of such notification, then Licensee
shall have no further claim or right with respect to the Proposed Transaction. Licensee may elect, in its sole discretion, not
to exercise its ROFR with respect to any Proposed Transaction, provided that any such election by Licensee shall not adversely
affect Licensee’s ROFR with respect to any other Proposed Transaction.”

 

		10.	A new Section 7.g. shall be added to the Third Addendum to read as follows: “Licensor shall
not solicit, negotiate or entertain any inquiry regarding the potential acquisition of the Cell-in-a-Box® Trademark
and its Associated Technology for a period of one (1) year from August 30, 2017.”

 

		11.	Except as provided in this Fourth Addendum, all the other provisions of the Agreements shall remain
in full force and effect.

 

		12.	This Fourth Addendum in no way alters or effects the terms of the Binding Memorandum of Understanding
entered into by and between PharmaCyte Biotech, Inc., and Austrianova Singapore Pte. Ltd. effective as of 28 July 2016.

 

		13.	This Fourth Addendum constitutes the entire, final and complete agreement and understanding between
the Parties and replaces and supersedes all prior discussions and agreements between them with respect to the subject matter of
the Fourth Addendum, including the Term Sheet. No amendment, modification or waiver of any terms or conditions of this Fourth Addendum
shall be effective unless made in writing and signed by a duly authorized officer of each Party.

 

		14.	This Fourth Addendum may be executed in counterparts, each of which shall be an original and all
of which shall constitute together the same document. The Parties agree that execution of this Fourth Addendum by exchanging facsimile,
PDF, or electronic signatures shall have the same legal force and effect as the exchange of original signatures.

 

IN WITNESS WHEREOF,
each Party has executed this Fourth Addendum by its duly authorized representative as of the Effective Date of the Fourth Addendum.

 

	PharmaCyte Biotech, Inc.	 	SG Austria Pte. Ltd.
	 	 	 
	 	 	 
	By: /s/ Dr. Kenneth L. Waggoner                    	 	By: /s/ Dr. Brian Salmons                    
	Printed Name: Dr. Kenneth L. Waggoner	 	Printed Name: Dr. Brian Salmons
	Title: Chief Executive Officer	 	Title: Chief Executive Officer
	Date: May 14, 2018	 	Date: May 14, 2018

 

 

 

 

    	 	3Exhibit 10.2

 

Third Amendment to Licensing Agreement

 

This Third Amendment
to the Licensing Agreement (“Third Amendment”) is effective on the date the parties have fully signed the Third
Addendum (“Effective Date of the Third Amendment”) and memorializes the agreement reached between PharmaCyte
Biotech, Inc., formerly Nuvilex, Inc. (“Licensee”), and Austrianova Singapore Pte Ltd (“Licensor”)
on 30 August 2017 relating to the Licensing Agreement between the Parties dated as of 1 December 2014, as amended by the First
Amendment to the Licensing Agreement dated as of June 30, 2015 and the Second Amendment to the Licensing Agreement dated as of
19 October 2015 (collectively, “Licensing Agreement”). Licensee and Licensor are referred to in this Third Amendment
individually as a “Party” and collectively as the “Parties.” Defined terms in the Licensing
Agreement have the same meaning in this Third Amendment as they do in the Licensing Agreement.

 

Recitals

 

		A.	The Parties entered into the Licensing Agreement to, among other things, provide Licensee with
an exclusive worldwide license to use the Cell-in-a-Box® Trademark and its Associated Technology with genetically
modified non-stem cell lines specifically designed to activate members of the Cannabinoid family of molecules to conduct research,
to use in preclinical studies and clinical trials, to obtain marketing approval and to market and sell products and treatments
utilizing the Cell-in-a-Box® Trademark and its Associated Technology world-wide;

 

		B.	Section 3.1.1 of the Licensing Agreement provides that Licensee shall pay to Licensor royalties
equal to ten percent (10%) of Gross Sales Value of all Products sold by Licensee. The Parties desire to change the amount of royalties
Licensee shall pay to Licensor in accordance with the amended Section 3.1.1 below;

 

		C.	Section 3.1.2 of the Licensing Agreement provides that Licensee shall pay to Licensor royalties
equal to twenty percent (20%) of the amount received by Licensee from Sub-Licensees on Sub-Licensees’ Gross Sales Value.
The Parties desire to change the amount of royalties Licensee shall pay to Licensor pursuant to Section 3.1.2 in accordance with
the amended Section 3.1.2. below;

 

		D.	Section 3.2 of the Licensing Agreement provides Licensee shall pay Licensor certain milestone payments
upon the occurrence of certain events (“Milestone Payments”). The Parties desire to delete Section 3.2 in its entirety
from the Licensing Agreement;

 

		E.	The Parties desire to add a new Section 3.2 to the Licensing Agreement in accordance with the new
Section 3.2 below;

 

		F.	The Parties desire to add a new Section 10.6 to the Licensing Agreement in accordance with the
new Section 10.6 below; and

 

		G.	The Parties desire to update the address of their registered office and principal place of business.

 

 

 

    	 	1	 

     

    

 

Agreement

 

For good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, the Licensing Agreement
is hereby amended as follows:

 

		1.	In the preamble to the Licensing Agreement, the address of the registered office and principal
place of business of Licensee shall be amended to read: “Austrianova Singapore Pte. Ltd., a Singapore corporation having
its registered office and principal place of business at 3 Biopolis Drive, #05-19 Synapse, Singapore 138623, Reg. No. 200705334K
and its Affiliates (“Licensor”), and”

 

		2.	In the preamble to the Licensing Agreement, the name of Licensee shall be amended to its new name
and address to read: “PharmaCyte Biotech, Inc., a Nevada corporation having its principal place of business at 23046 Avenida
de la Carlota, Suite 600, Laguna Hills, California 92653 USA and its Affiliates (“Licensee”).”

 

		3.	Section 3 of the Licensing Agreement shall be deleted and the following inserted in its place:
“Royalties and Other Consideration.”

 

		4.	Section 3.1.1 of the Licensing Agreement shall be deleted and the following inserted in its place:
“Four percent (4%) of Gross Sales Value of all Products sold by Licensee; and”

 

		5.	Section 3.1.2 of the Licensing Agreement shall be deleted and the following inserted in its place:
“Twenty percent (20%) of the amount received by Licensee from Sub-Licensees on Sub-Licensees Gross Sales Value; provided,
however, that in the event the sublicensing royalty rate received by Licensee is four percent (4%) or less, Licensor shall
receive fifty percent (50%) of the amount of money received by Licensee from Sub-Licensees. For any amount received by Licensee
over the sublicensing royalty rate of four percent (4%), Licensor shall receive twenty percent (20%) of that amount.” For
the avoidance of doubt the following two examples are given. Example 1: Sub-Licensee has a Gross Sales Value of One Thousand Dollars
US (US$1000.00). Licensee receives a four percent (4%) royalty rate from Sub-Licensee equal to Forty Dollars US (US$40.00). In
this example, Licensee pays Licensor 50% of this royalty in the amount of Twenty Dollars US (US$20.00). Example 2: Sub-Licensee
has a Gross Sales Value of One Thousand Dollars US (US$1000.00). Licensee receives a six percent (6%) royalty rate from Sub-Licensee
in the amount of Sixty Dollars US (US$60.00) USD). In this example, Licensee pays Licensor 50% of the amount corresponding to a
four percent royalty in the amount of Twenty Dollars US (US$20.00) and twenty percent (20%) of the amount over four percent (4%)
(20% of US$20.00 is equal to US$4.00) to give a total royalty to Licensor of Twenty-Four Dollars US (US$24.00).

 

		6.	Section 3.2 shall be deleted and the following inserted in its place: “Other Consideration.
Subject to the terms of this Agreement, Licensee shall pay to Licensor other consideration of:”

 

		7.	Sections 3.2.1, 3.2.2, 3.2.3. and 3.2.4 of the Licensing Agreement shall be deleted and the following
Section 3.2.1. inserted in their place: “Except as otherwise provided in Section 3.1.2, Licensor shall receive fifty percent
(50%) of any other financial and non-financial consideration Licensee receives from a Sub-Licensee.”

 

 

 

    	 	2	 

     

    

 

		8.	Section 3.3 of the Licensing Agreement shall be deleted and the following inserted in its place:
“Quarterly Payments. All payments due pursuant to Section 3.1.1 shall be paid within thirty (30) days of the end of
the relevant calendar quarter. All payments due pursuant to Sections 3.1.2 and 3.2.1 shall be paid within forty-five (45) days
after the calendar quarter in which the payment is received by Licensee from a Sub-Licensee.”

 

		9.	A new Section 11.16 shall be added to the Licensing Agreement to read as follows: “Licensor
shall not solicit, negotiate or entertain any inquiry regarding the potential acquisition of the Cell-in-a-Box®
Trademark and its Associated Technology for a period of one (1) year from August 30, 2017”

 

		10.	Except as provided in this Second Amendment, all the other provisions of the Licensing Agreement
shall remain in full force and effect.

 

		11.	This Third Amendment constitutes the entire, final and complete agreement and understanding between
the Parties and replaces and supersedes all prior discussions and agreements between them with respect to the subject matter of
this Second Amendment, including the Binding Term Sheet between the Parties and SG Austria dated 30 August 2017. No amendment,
modification or waiver of any terms or conditions of this Second Amendment shall be effective unless made in writing and signed
by a duly authorized officer of each Party.

 

		12.	This Third Amendment may be executed in counterparts, each of which shall be an original and all
of which shall constitute together the same document. The Parties agree that execution of this Second Amendment by exchanging facsimile,
PDF, or electronic signatures shall have the same legal force and effect as the exchange of original signatures.

 

IN WITNESS WHEREOF,
each Party has executed this Second Amendment by its duly authorized representative as of the Effective Date of the Third Amendment.

 

	PharmaCyte Biotech, Inc.	 	Austrianova Singapore Pte. Ltd.
	 	 	 
	 	 	 
	By: /s/ Dr. Kenneth L. Waggoner                    	 	By: /s/ Dr. Brian Salmons                    
	Printed Name: Dr. Kenneth L. Waggoner	 	Printed Name: Dr. Brian Salmons
	Title: Chief Executive Officer	 	Title: Chief Executive Officer
	Date: May 14, 2018	 	Date: May 14, 2018

 

 

 

 

 

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]